Company Description
ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems...
ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.
Valuation
P/E Current
35.50
P/E Ratio (with extraordinary items)
96.17
P/E Ratio (without extraordinary items)
50.12
Price to Sales Ratio
3.93
Price to Book Ratio
3.13
Price to Cash Flow Ratio
19.32
Enterprise Value to EBITDA
14.73
Enterprise Value to Sales
2.27
Efficiency
Total Asset Turnover
0.72
Liquidity
Current Ratio
5.07
Quick Ratio
3.62
Cash Ratio
2.83
Profitability
Gross Margin
36.35
Operating Margin
10.48
Pretax Margin
9.36
Net Margin
7.84
Return on Assets
5.66
Return on Equity
6.61
Return on Total Capital
8.58
Capital Structure
Total Debt to Total Assets
2.43
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Vivek Jain | 47 | 2014 | Chairman & Chief Executive Officer |
Mr. Christian Voigtlander | 51 | 2017 | Vice President-Business Development |
Mr. Brian M. Bonnell | - | 2018 | Vice President-Finance |
Mr. Krishna Uppugonduri | - | 2015 | VP-Quality, Medical & Regulatory Affairs |
Mr. Daniel Woolson | 43 | 2017 | Vice President & General Manager-Infusion Systems |
Insider Actions
05/23/2022 |
Vivek Jain Chairman and CEO; Director |
30 | Gift at $0 per share. | 0 |
05/13/2022 |
Elisha Wade Finney Director |
743 | Gift at $0 per share. | 0 |
05/12/2022 |
George A. Lopez Director |
17 | Acquisition at $174.66 per share. | 2,969 |
05/12/2022 |
George A. Lopez Director |
9,329 | Acquisition at $174.17 per share. | 1,624,831 |
05/12/2022 |
George A. Lopez Director |
7,092 | Acquisition at $173.07 per share. | 1,227,412 |
05/12/2022 |
George A. Lopez Director |
4,917 | Acquisition at $172.24 per share. | 846,904 |
05/12/2022 |
George A. Lopez Director |
4,480 | Acquisition at $170.79 per share. | 765,139 |
05/12/2022 |
Virginia Sanzone VP, General Counsel |
750 | Disposition at $173.56 per share. | 130,170 |
05/12/2022 |
Elisha Wade Finney Director |
217 | Disposition at $170.53 per share. | 37,005 |
05/11/2022 |
David C. Greenberg Director |
433 | Derivative/Non-derivative trans. at $0 per share. | 0 |
05/11/2022 |
David F. Hoffmeister Director |
433 | Derivative/Non-derivative trans. at $0 per share. | 0 |
05/11/2022 |
Donald M. Abbey Director |
433 | Derivative/Non-derivative trans. at $0 per share. | 0 |
05/11/2022 |
Elisha Wade Finney Director |
433 | Derivative/Non-derivative trans. at $0 per share. | 0 |
05/11/2022 |
Laurie Hernandez Director |
352 | Derivative/Non-derivative trans. at $0 per share. | 0 |
05/11/2022 |
Kolleen T. Kennedy Director |
129 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Vivek Jain Chairman and CEO; Director |
1,328 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Christian B. Voigtlander Chief Operating Officer |
1,163 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Daniel Woolson VP, GM-Infusion Capital |
894 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Brian M. Bonnell Chief Financial Officer |
1,163 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Kevin J. McGrody Chief Accounting Officer |
442 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Virginia Sanzone VP, General Counsel |
1,196 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Vivek Jain Chairman and CEO; Director |
2,524 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Christian B. Voigtlander Chief Operating Officer |
2,209 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Daniel Woolson VP, GM-Infusion Capital |
2,020 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Brian M. Bonnell Chief Financial Officer |
2,209 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Kevin J. McGrody Chief Accounting Officer |
841 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2022 |
Virginia Sanzone VP, General Counsel |
2,272 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Vivek Jain Chairman and CEO; Director |
760 | Derivative/Non-derivative trans. at $242.93 per share. | 184,626 |
03/06/2022 |
Vivek Jain Chairman and CEO; Director |
932 | Derivative/Non-derivative trans. at $242.93 per share. | 226,410 |
03/06/2022 |
Christian B. Voigtlander Chief Operating Officer |
816 | Derivative/Non-derivative trans. at $242.93 per share. | 198,230 |
03/06/2022 |
Christian B. Voigtlander Chief Operating Officer |
760 | Derivative/Non-derivative trans. at $242.93 per share. | 184,626 |
03/06/2022 |
Daniel Woolson VP, GM-Infusion Capital |
628 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Daniel Woolson VP, GM-Infusion Capital |
639 | Derivative/Non-derivative trans. at $242.93 per share. | 155,232 |
03/06/2022 |
Brian M. Bonnell Chief Financial Officer |
816 | Derivative/Non-derivative trans. at $242.93 per share. | 198,230 |
03/06/2022 |
Brian M. Bonnell Chief Financial Officer |
380 | Derivative/Non-derivative trans. at $242.93 per share. | 92,313 |
03/06/2022 |
Kevin J. McGrody Chief Accounting Officer |
466 | Derivative/Non-derivative trans. at $242.93 per share. | 113,205 |
03/06/2022 |
Kevin J. McGrody Chief Accounting Officer |
532 | Derivative/Non-derivative trans. at $242.93 per share. | 129,238 |
03/06/2022 |
Virginia Sanzone VP, General Counsel |
839 | Derivative/Non-derivative trans. at $242.93 per share. | 203,818 |
03/06/2022 |
Virginia Sanzone VP, General Counsel |
760 | Derivative/Non-derivative trans. at $242.93 per share. | 184,626 |
03/06/2022 |
Vivek Jain Chairman and CEO; Director |
1,444 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Vivek Jain Chairman and CEO; Director |
1,772 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Christian B. Voigtlander Chief Operating Officer |
1,551 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Christian B. Voigtlander Chief Operating Officer |
1,444 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Daniel Woolson VP, GM-Infusion Capital |
1,418 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Daniel Woolson VP, GM-Infusion Capital |
1,444 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Brian M. Bonnell Chief Financial Officer |
1,551 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Brian M. Bonnell Chief Financial Officer |
722 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Kevin J. McGrody Chief Accounting Officer |
886 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Kevin J. McGrody Chief Accounting Officer |
1,011 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Virginia Sanzone VP, General Counsel |
1,595 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2022 |
Virginia Sanzone VP, General Counsel |
1,444 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/03/2022 |
Vivek Jain Chairman and CEO; Director |
36,000 | Disposition at $240 per share. | 8,640,000 |
03/03/2022 |
Vivek Jain Chairman and CEO; Director |
36,000 | Derivative/Non-derivative trans. at $58.79 per share. | 2,116,440 |
12/30/2021 |
Vivek Jain Chairman and CEO; Director |
1,159 | Disposition at $240 per share. | 278,160 |
12/30/2021 |
Vivek Jain Chairman and CEO; Director |
1,159 | Derivative/Non-derivative trans. at $58.79 per share. | 68,137 |
12/29/2021 |
Vivek Jain Chairman and CEO; Director |
10,677 | Disposition at $240 per share. | 2,562,480 |
12/29/2021 |
Vivek Jain Chairman and CEO; Director |
10,677 | Derivative/Non-derivative trans. at $58.79 per share. | 627,700 |
12/28/2021 |
Vivek Jain Chairman and CEO; Director |
164 | Disposition at $240 per share. | 39,360 |
12/28/2021 |
Vivek Jain Chairman and CEO; Director |
164 | Derivative/Non-derivative trans. at $58.79 per share. | 9,641 |
MarketWatch News on ICUI
-
Edwards Lifesciences Corp. stock falls Friday, still outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Thursday, still outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Wednesday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Friday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market despite losses on the day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Monday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Thursday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Friday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Thursday, still outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Friday, underperforms market
- MarketWatch Automation
- Loading more headlines...
Other News on ICUI
-
Bausch + Lomb: Shares Deserve Some Upside
- Seeking Alpha
-
ICU Medical, Inc. 2022 Q1 - Results - Earnings Call Presentation
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Notable earnings after Monday's close
- Seeking Alpha
-
ICU Medical (ICUI) Investor Presentation - Slideshow
- Seeking Alpha
-
Meridian Bioscience: Deceptively Priced
- Seeking Alpha
-
ICU Medical, Inc. 2021 Q4 - Results - Earnings Call Presentation
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
- Loading more headlines...